1. Antiplatelet for Coronary Artery Disease in Specific Condition "No Size Fits All".
- Author
-
Setiadi BM, Hartono B, Prakoso AB, Lubis AC, Munandar RM, and Munawar M
- Subjects
- Hemorrhage drug therapy, Humans, Platelet Aggregation Inhibitors adverse effects, Coronary Artery Disease drug therapy, Hemorrhage complications, Platelet Aggregation Inhibitors therapeutic use
- Abstract
Antiplatelet is the cornerstone therapy for patient with coronary artery disease. Several comorbidities can influence the efficacy and safety of antiplatelet agent. Diabetes mellitus is characterized by increased platelet reactivity and reduced response to antiplatelet. Elderly patients have both reduced response to antiplatelet and increased risk of bleeding. Patients with renal dysfunction also had decreased efficacy of antiplatelet accompanied with increased risk of bleeding. In patients with atrial fibrillation, the concomitant use of anticoagulant with antiplatelet poses an increased risk of bleeding. In patients with these comorbidities, caution should be stressed in selecting the best regimen of antiplatelet which translates the most optimal efficacy while minimizing the risk of adverse events. In this review, we will discuss the platelet changes in these comorbidities, current evidence of antiplatelet usage in these group of patients and current recommendation., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
- Published
- 2018
- Full Text
- View/download PDF